Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Celcuity Inc

CELC ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$92.00

▲ +6.24%

Market Cap $4.50B · Vol 356.10K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.50B

Mid Cap

Div Yield

N/A

EPS Growth

-16.19%

YoY

RSI (14)

64.53

Momentum

Beta

0.20

vs Market

52W High

$151.02

39.08% below

52W Low

$44.67

105.95% above

Volume

356.10K

Avg 397.92K

P/B

47.85

Price-to-book

ROE

N/A

Return on equity

Free Float

83.62%

Public shares

Shariah Compliance8 STANDARDS

✗ Celcuity Inc (CELC) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CELC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.84%

-17.15%

-31.71%

-11.97%

YTD

-7.76%

+77.30%

+832.12%

+331.52%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-177,042,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-49.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	47.85
P/FCF	N/A
EPS Growth	-16.19%
Outstanding Shares	48.93M

Technical Indicators

50-Day SMA	$93.58
200-Day SMA	$105.14
RSI (14)	64.53
Beta	0.20
52-Week High	$151.02
52-Week Low	$44.67

Volume Today	356.10K
Avg Daily Volume (30D)	397.92K
Relative Volume	0.89x
Volatility (10D)	57.96
Volatility (30D)	81.55
Free Float	83.62%

Analyst Consensus

BUY

Current Price $92.00

Mean Target $160.64

52W Low$44.67 52W High$151.02

Current

Target

$44.67 $151.02

Current Analyst target

+74.60% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00HKBW054

ISINUS15102K1007

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.